» Articles » PMID: 12358435

Targeting a KH-domain Protein with RNA Decoys

Overview
Journal RNA
Specialty Molecular Biology
Date 2002 Oct 3
PMID 12358435
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

RNA-binding proteins are involved in the regulation of many aspects of eukaryotic gene expression. Targeted interference with RNA-protein interactions could offer novel approaches to modulation of expression profiles, alteration of developmental pathways, and reversal of certain disease processes. Here we investigate a decoy strategy for the study of the alphaCP subgroup of KH-domain RNA-binding proteins. These poly(C)-binding proteins have been implicated in a wide spectrum of posttranscriptional controls. Three categories of RNA decoys to alphaCPs were studied: poly(C) homopolymers, native mRNA-binding sites, and a high-affinity structure selected from a combinatorial library. Native chemistry was found to be essential for alphaCP decoy action. Because alphaCP proteins are found in both the nucleus and cytoplasm, decoy cassettes were incorporated within both nuclear (U1 snRNA) and cytoplasmic (VA1 RNA) RNA frameworks. Several sequences demonstrated optimal decoy properties when assayed for protein-binding and decoy bioactivity in vitro. A subset of these transcripts was shown to mediate targeted inhibition of alphaCP-dependent translation when expressed in either the nucleus or cytoplasm of transfected cells. Significantly, these studies establish the feasibility of developing RNA decoys that can selectively target biologic functions of abundant and widely expressed RNA binding proteins.

Citing Articles

RNA-Binding Proteins PCBP1 and PCBP2 Are Critical Determinants of Murine Erythropoiesis.

Ji X, Jha A, Humenik J, Ghanem L, Kromer A, Duncan-Lewis C Mol Cell Biol. 2021; 41(9):e0066820.

PMID: 34180713 PMC: 8384066. DOI: 10.1128/MCB.00668-20.


The regulation of RNA metabolism in hormone signaling and breast cancer.

Wang X, Yang D Mol Cell Endocrinol. 2021; 529:111221.

PMID: 33711334 PMC: 8262629. DOI: 10.1016/j.mce.2021.111221.


BOPC1 Enantiomers Preparation and HuR Interaction Study. From Molecular Modeling to a Curious DEEP-STD NMR Application.

Volpe S, Listro R, Parafioriti M, Di Giacomo M, Rossi D, Ambrosio F ACS Med Chem Lett. 2020; 11(5):883-888.

PMID: 32435400 PMC: 7236254. DOI: 10.1021/acsmedchemlett.9b00659.


P-element Somatic Inhibitor Protein Binding a Target Sequence in Pre-mRNA Conserved in and .

Wang Y, Zhao Q, Wan Q, Wang K, Zha X Int J Mol Sci. 2019; 20(9).

PMID: 31086020 PMC: 6539025. DOI: 10.3390/ijms20092361.


PolyC-binding proteins enhance expression of the CDK2 cell cycle regulatory protein via alternative splicing.

Ji X, Humenik J, Yang D, Liebhaber S Nucleic Acids Res. 2017; 46(4):2030-2044.

PMID: 29253178 PMC: 5829739. DOI: 10.1093/nar/gkx1255.


References
1.
Conn G, Draper D . RNA structure. Curr Opin Struct Biol. 1998; 8(3):278-85. DOI: 10.1016/s0959-440x(98)80059-6. View

2.
Russell J, Morales J, Makeyev A, Liebhaber S . Sequence divergence in the 3' untranslated regions of human zeta- and alpha-globin mRNAs mediates a difference in their stabilities and contributes to efficient alpha-to-zeta gene development switching. Mol Cell Biol. 1998; 18(4):2173-83. PMC: 121457. DOI: 10.1128/MCB.18.4.2173. View

3.
Collier B, Sokolowski M, Schwartz S . Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogenous ribonucleoprotein K and poly(rC)-binding proteins 1 and 2. J Biol Chem. 1998; 273(35):22648-56. DOI: 10.1074/jbc.273.35.22648. View

4.
Penolazzi L, Lambertini E, Aguiari G, del Senno L, Piva R . Modulation of estrogen receptor gene expression in human breast cancer cells: a decoy strategy with specific PCR-generated DNA fragments. Breast Cancer Res Treat. 1998; 49(3):227-35. DOI: 10.1023/a:1006060523381. View

5.
Barcellini-Couget S, Fenard D, Bertrand E, Singer R, Lefebvre J, Doglio A . 3'-End modification of the adenoviral VA1 gene affects its expression in human cells: consequences for the design of chimeric VA1 RNA ribozymes. Antisense Nucleic Acid Drug Dev. 1998; 8(5):379-90. DOI: 10.1089/oli.1.1998.8.379. View